Astrazeneca Pharma India Ltd vs Sms Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8243 as of 12 Jun 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of SMS Pharmaceuticals Ltd changed from 16.8 on March 2021 to 27.3 on March 2025 . This represents a CAGR of 10.20% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of SMS Pharmaceuticals Ltd changed from ₹ 1053 crore on March 2021 to ₹ 1885 crore on March 2025 . This represents a CAGR of 12.36% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of SMS Pharmaceuticals Ltd for the Mar '26 is ₹ 240.52 crore as compare to the Dec '25 revenue of ₹ 214.2 crore. This represent the growth of 12.29% The ebitda of Astrazeneca Pharma India Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of SMS Pharmaceuticals Ltd for the Mar '26 is ₹ 42.47 crore as compare to the Dec '25 ebitda of ₹ 47.4 crore. This represent the decline of -10.4% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of SMS Pharmaceuticals Ltd changed from ₹ 16.37 crore to ₹ 20.96 crore over 8 quarters. This represents a CAGR of 13.15% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of SMS Pharmaceuticals Ltd changed from 4.17 % on March 2021 to 5.19 % on March 2025 . This represents a CAGR of 4.47% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Limited was incorporated in December, 1987.
The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates.
Apart from R &D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh. During the year 2015, the company has re-enforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities. During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24. During the year 2014-15, the Company acquired 12,25,900 equity shares of Rs. 10/- each in M/s.
VKT Pharma Private Limited.

FAQs for the comparison of Astrazeneca Pharma India Ltd and SMS Pharmaceuticals Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or SMS Pharmaceuticals Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,609 Cr while Market cap of SMS Pharmaceuticals Ltd is 3,600 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and SMS Pharmaceuticals Ltd?

The stock performance of Astrazeneca Pharma India Ltd and SMS Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and SMS Pharmaceuticals Ltd?

As of June 14, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8243.9. On the other hand, SMS Pharmaceuticals Ltd stock price is INR ₹384.45.

How do dividend payouts of Astrazeneca Pharma India Ltd and SMS Pharmaceuticals Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and SMS Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.